CliffBio
small molecule

RIVASTIGMINE TARTRATE

RIVASTIGMINE TARTRATE

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameRIVASTIGMINE TARTRATE
Active ingredientRIVASTIGMINE TARTRATE
StrengthEQ 3MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalMay 2013
Marketing statusDISCN

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.